icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 22-26 2022
Back grey_arrow_rt.gif
 
 
 
Eight Weeks of Glecaprevir/Pibrentasvir is Well Tolerated and Yields High Sustained Virological Response in HCV-Infected Treatment-Naïve Patients With Compensated Cirrhosis: Final Results From the CREST Study
 
 
  EASL 2022 June 22-26 London
 
M. Cornberg1, A. Abergel2, A. Aghemo3, A. Ahumada4, M. Andreoni5, T. Asselah6, A. Bhagat7, M. Bondin7, I. Butrymowicz7, M. Carmiel8, G. Chodick9,10, B. Conway11, A. Gasbarrini12, D. Hüppe13, F. Jorquera Plaza14, P. Lampertico15,16, M.L. Manzano Alonso17, L. Myles18, M. Persico19, A. Ramji20, C. Sarrazin21, D. Semizarov7, Y. Song7, S. Sonparote7, E. Villa22, C. Weil9, J.I. Uriz Otano23,24 and The CREST Study Group

0622221

0622222

0622223

0622224

0622225

0622226

0622227

0622228

0622229

06222210